We have in development an innovative dermatological treatment specialized to treat against atopic dermatitis and other dermatological conditions. Infused with our tested pure CBD, our CaniSkin topical cream may provide soothing properties along with revolutionary healing results. This product is intended for sale OTC. Last year, the drug Dupixent, the new and leading treatment for atopic dermatitis of 2018 achieved sales of $319 million along with FDA approval.
We initiated our first clinical study to investigate a novel cannabidiol lotion for the treatment of atopic dermatitis (Eczema) in Q4 2019.
We anticipate expanding on our clinical trials in 2020 with additional studies aimed as exploring the efficacy of our patented Cox-2 inhibitor combined with our propitiatory CBD skin creams.
We have acquired two patents through our acquisition of HealthAide and have one patent pending on the combination of these with CBD.